Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

Running, not enrolling · Phase 2

Conditions studied: Heart Failure Preserved Ejection Fraction, Resistant Hypertension

In brief

African American adults in the United States have the highest prevalence rate of high blood pressure (hypertension) and heart failure in the world. African Americans with treatment resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to Caucasians. This trial will test if administration of the xanthine oxidase inhibitor - Allopurinol (commonly used in the treatment of gout), given over a period of 8 weeks, will improve heart function, exercise ability and quality of life in African American Veterans with resistant hypertension.

Key facts

Study ID
NCT05888233
Run by
VA Office of Research and Development
People needed
40
Starts
2024-09-30
Expected to finish
2026-08-31
Last updated by the study team
2026-07-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.